Sage plots comeback plan for its experimental oral antidepressant
Trials testing depression drugs invariably tend to disappoint. Perhaps the most keenly-anticipated depression trial of 2019, despite great analyst and investor optimism, also failed in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.